

1 Article

# 2 The Feasibility of Studying Metabolites in PICU 3 Multi-Organ Dysfunction Syndrome Patients Over 4 an 8-day Course Using An Untargeted Approach

5 Mara L. Leimanis-Laurens, PhD<sup>1,2\*</sup>, Danny Gil, MD<sup>1,2\*</sup>, Andrew Kampfshulte, MS<sup>3</sup>, Claire  
6 Krohn, MD(2021)<sup>4</sup>, Elizabeth Prentice, DO<sup>1,2</sup>, Dominic Sanfilippo, MD<sup>1,2</sup>, Jeremy W. Prokop,  
7 PhD<sup>2,5</sup>, Todd Lydic, PhD<sup>6</sup>, Surender Rajasekaran, MD, MPH<sup>1,2,3</sup>

8 <sup>1</sup>Pediatric Critical Care Unit, Helen DeVos Children's Hospital, 100 Michigan Street NE, Grand Rapids, MI,  
9 49503

10 <sup>2</sup>Department of Pediatrics and Human Development, College of Human Medicine, Michigan State  
11 University, Life Sciences Building, 1355 Bogue Street, East Lansing, MI, 48824

12 <sup>3</sup>Spectrum Health, 100 Michigan Street NE, Grand Rapids, MI, 49503

13 <sup>4</sup>Michigan State University, College of Human Medicine, 15 Michigan Street NE, Grand Rapids, MI, 49503

14 <sup>5</sup>Department of Pharmacology and Toxicology, Michigan State University, 1355 Bogue Street, East Lansing,  
15 MI, 48824, United States

16 <sup>6</sup>Department of Physiology, Collaborative Mass Spectrometry Core, 578 S. Shaw Ln. Chemistry  
17 Building, Michigan State University, East Lansing, MI 48824

18

19 \*Authors contributed equally to this work

20 \*Correspondence: E-mail: mara.leimanis@spectrumhealth.org; Tel.: (+1 616-267-0106)

21 Received: date; Accepted: date; Published: date

22 **Abstract:** Metabolites are generated from critical biological functions and metabolism. This  
23 pediatric study reviewed plasma metabolites in patients suffering from multi-organ dysfunction  
24 syndrome (MODS) in the pediatric intensive care unit (PICU) using an untargeted metabolomics  
25 approach. Patients meeting criteria for MODS were screened for eligibility and consented (n=24),  
26 and blood samples were collected at baseline, 72 hours, and 8 days; control patients (n=4), were  
27 presenting for routine sedation in an outpatient setting. A sub-set of MODS patients (n=8) required  
28 additional support with veno-atrial extracorporeal membrane oxygenation (VA-ECMO) therapy.  
29 Metabolites from thawed blood plasma were determined from ion pairing reversed-phase LC-MS  
30 analysis. Chromatographic peak alignment, identification, relative quantitation, statistical and  
31 bioinformatics evaluation were performed using MAVEN and MetaboAnalyst 4.0. Metabolite  
32 analysis revealed 115 peaks per sample. From the PLS-DA with VIP scores above  $\geq 2.0$ , 7 dynamic  
33 metabolites emerged over the 3 time points: tauro-chenodeoxycholic acid (TCDC), hexose, *p*-  
34 hydroxybenzoate, hydroxyphenylacetic acid (HPLA), 2\_3-dihydroxybenzoic acid, 2-keto-  
35 isovalerate, and deoxyribose phosphate. After Bonferonni adjustment for repeated measures  
36 hexose and *p*-hydroxybenzoate were significant at one time point, or more. Kendall's tau-b test  
37 was used for internal validation of creatinine. Metabolites may be benign or significant in  
38 describing a patient's pathophysiology and require operator interpretation.

39 **Keywords:** blood plasma, extracorporeal membrane oxygenation, metabolites, multiple organ  
40 dysfunction syndrome, pediatric intensive care unit, liquid chromatography mass spectrometry

## 41 1. Introduction

42 The ability to identify, quantify, and analyze the metabolic profile of a pediatric patient, allows  
43 us to investigate the interaction between both physiologic and pathologic states. Metabolites are  
44 under the control of environmental pressures, such as nutrition [1], viral infections (such as Covid-  
45 19 [2], Ebola [3]), gut bacterial composition and cancer [4], medications [5,6], and a patient's own pre-  
46 existing genetic make-up [7]. Metabolites, being low molecular weight molecules and/or products

47 of metabolic pathways, are growing in appeal medically over the last decade for their potential in  
48 disease characterization, drug discovery and precision medicine [8,9].

49 We have previously described the current cohort of patients for patient whole blood  
50 transcriptomics [10,11], and plasma lipidome [12]. This has revealed a complex biology in a  
51 heterogenous patient population with a non-uniform patient response to treatments over an 8-day  
52 course (stabilization and recovery phases) of illness during a PICU admission. Complimentary to  
53 these previously reported analytic modalities from whole blood [10-12], the aim of this current report  
54 was two-fold: 1) to characterize total blood plasma metabolites (polar, charged) using an untargeted  
55 approach, 2) to determine change in metabolites over an 8-day PICU course. There is a gap in our  
56 understanding of the complex interaction between pediatric critical illness, specifically multi-organ  
57 dysfunction syndrome (MODS) [13] (affecting twenty percent of PICU admissions [14], resulting in  
58 ten times the mortality rate [15]), and their respective blood metabolites.

## 59 **2. Materials and Methods**

### 60 *2.1 Study Population, Site and Sample Collection*

61 After IRB approval, a short-term longitudinal design was adopted at Helen DeVos Children's  
62 Hospital (2016-062-SH/HDVCH). Samples were collected under the protocol and study design [10-  
63 12] in a quaternary-care, urban, pediatric hospital in Western, Michigan. In brief, patients who were  
64 identified as having MODS were enrolled, 24 in total, with an additional 4 sedation-control patients.  
65 These 24 patients were then further classified as needing veno-arterial extracorporeal membrane  
66 oxygenation (VA-ECMO) as a therapeutic modality (n=8) according to Extracorporeal Life Support  
67 Organization (ELSO) criteria [16]. Blood samples from the patients were obtained and placed into  
68 EDTA-filled tubes, plasma was processed and stored at -80 ° C for later use. All samples had  
69 undergone one freeze-thaw before processing and analysis.

### 71 *2.2 Metabolite Extraction and Liquid Chromatography-Mass Spectrometry (LC-MS)*

72  
73 Plasma samples (~50 microliters) were subjected to biphasic extraction using  
74 chloroform/methanol/water as described previously [17] to remove nonpolar matrix interferences  
75 and recover polar metabolites in the aqueous extraction phase. Stable isotope labeled (D<sup>4</sup>)-succinate  
76 was added to plasma during extraction for use in estimation of metabolite recovery and for relative  
77 quantitation across experimental groups. Samples were filtered through 0.2 micron syringe filters  
78 (Fisher Scientific) and reconstituted in 100 microliters of 50 % methanol for use in ion pairing  
79 reversed-phase LC-MS analysis.

80 Targeted polar metabolite identification utilized a Thermo Scientific model TSQ Vantage triple  
81 quadrupole mass spectrometer operating in negative ion mode. The mass spectrometer was  
82 coupled to a Shimadzu Prominence HPLC with thermostated column oven and autosampler. Ten  
83 microliter sample injections were subjected to gradient elution with (A) 10 mM tributylamine and 15  
84 mM acetic acid (pH 4.95), and (B) Methanol according to B. Luo, et al. [18], with separation of  
85 metabolites achieved on a Phenomenex Synergi Hydro-RP C18 column (2.0 mm x 150 mm, 3 micron  
86 particles, 80 Angstrom pore size). The column was protected by a Phenomenex guard cartridge of  
87 identical chemistry. Metabolites were identified and quantitated by selected ion monitoring.  
88 Detection parameters for each precursor/product ion pair of interest have been optimized based  
89 using commercially available standards.

### 91 *2.3 Data analysis*

92  
93 LC-MS data analysis of chromatographic peak alignment, compound identification, relative  
94 quantitation, and statistical evaluation across experimental groups will be performed using MAVEN  
95 software [19]. Only relative quantitation of analytes against a selected internal standard was  
96 performed for comparison of values across experimental treatment groups. "Absolute" quantitation

97 was not carried out in these experiments. Metabolites as listed in Supplemental Table 1, were  
98 initially categorized as anabolic vs. catabolic and endogenous vs. exogenous according to Human  
99 Metabolite Data Base (HMDB) (<https://hmdb.ca/metabolites/>) (Supplemental Figure 1).

100 Metabolic profiles for sedation-controls were compared to MODS or ECMO patients, quantified  
101 as percent of total. Metabolites with >30% of cases with zero values were excluded from further  
102 analysis; consequently 66 metabolites were analyzed over the three time points (Figure 1). Using  
103 MetaboAnalyst 4.0 [20], data were normalized using pareto scaling (mean-centered and divided by  
104 the square root of standard deviation of each variable), and subjected to a multi-variate partial least  
105 squares-discriminant analysis (PLS-DA) analysis [21], using Q2 values for cross-validation [22]. No  
106 data points were excluded. To assess the significance of class discrimination, a permutation test was  
107 performed and PLS-DA model built [between the data (X) and the permuted class labels (Y)] using  
108 the optimal number of components as determined by cross validation for the model based on the  
109 original class assignment [23]. This guided analysis allowed for the display of each specific group  
110 assignment. Variable Importance in Projection (VIP) is a weighted sum of squares of the PLS  
111 loadings considering the amount of explained Y-variation in each dimension.

112 Univariate analysis was performed using MedCalc (MedCalc Software Ltd, Ostend, Belgium)  
113 for candidate metabolites as determined by variance of importance (VIP) scores >2.0 from seven  
114 metabolites, using independent T-tests (equal variances), and Welch-test (unequal variances). A  
115 Bonferroni correction of P-value (<0.008) was used to identify statistically significant associations  
116 with metabolites (to control for Type I errors), which was calculated by dividing the significance  
117 threshold of 0.05 by the number of repeated measures; in this case MODS and ECMO compared to  
118 sedation-controls (at baseline, time 72hrs and 8 days). Box and whisker plots were generated for the  
119 two remaining metabolites of interest, which included the median, the interquartile range (box), the  
120 outer range (whiskers) to pictorially summarize the central tendency, dispersion, skewness, and  
121 extremes of the dataset [24].

## 122 3. Results

### 123 3.1 Metabolite Ontology and Origin


124 All 115 metabolites are listed in Supplemental Table 1 according to compound identification  
125 from the metabolic mass to charge ratio and retention time. From here we looked at the ontology of  
126 the metabolites in order to characterize according to any known function and origin. We found that  
127 the majority of metabolites detected were endogenous in nature (76%), and associated with catabolic  
128 (38%), anabolic (35%), both catabolic and anabolic metabolism (14%), or unspecified mechanisms of  
129 action (13%) (Supplement Figure 1 A & B), according to HMDB (<https://hmdb.ca/metabolites/>).

### 130 3.2 Bioinformatic Analysis

131 Analytical flow chart is presented in Figure 1. Percent total of metabolites and change over time  
132 were visualized using supervised analysis PLS-DA, which revealed clustering of ECMO patients  
133 within the MODS patients over the three time points, as compared to the sedation-control group  
134 (Figure 2, A, B, C). These groupings were also visualized by heatmap analysis (Supplemental Figure  
135 2, A, B, C), supporting the initial finding of the PLS-DA, whereby the sedation-control patients were  
136 found to cluster amongst themselves.  
137  
138  
139

140

**Figure 1: Overview-untargeted analysis**




141

142

143

144

**Figure 2: PLS-DA plot of all patient samples at baseline (A), 72 hours (B), and 8 days (C)**



145

146

147

148

**Figure 2: Insert: PLS-DA classification using different number of components. The red star indicates the best classifier.**

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

The important features as identifies by the PLS-DA at baseline (Figure 3A), at 72 hours (Figure 3B) and at 8 days (Figure 3C), reveal seven metabolites with relative concentrations of the corresponding metabolite in each group under study. In total seven metabolites of interest emerged over the 3 time points: tauro-chenodeoxycholic acid (TCDDCA)-a conjugated bile acid, hexose-monosaccharide-simple sugar, p-hydroxybenzoate-biocide-antimicrobial agent/tyrosine, tryptophan, phenylalanine metabolite, hydroxyphenylacetic acid (HPLA)-metabolite of phenylalanine, 2\_3-dihydroxybenzoic acid-drug metabolite, 2-keto-isovalerate-cellular intermediate for the synthesis of branched-chain amino acids, deoxyribose phosphate-a pentose phosphate.


Starting with HPLA (with a VIP score  $\geq 1.5$  at 8 days) over the 3-time points, sedation-control values are consistently highest, with ECMO patients demonstrating an intermediate profile and MODS patients with the lowest values according to the relative concentrations. 2\_3-dihydroxybenzoic acid and deoxyribose-phosphate share similar relative concentration profiles to HPLA with the values highest for sedation-control patients compared to MODS with the lowest relative concentrations.

In the exact opposite profile is hexose, which reveals the highest relative concentrations values in MODS patients as compared to sedation-controls, again with ECMO sharing intermediate profiles at baseline. By day 8 however, this has changed completely, whereby sedation-controls have the highest relative concentrations, and ECMO the lowest, with MODS demonstrating intermediate profiles. We may extrapolate from this that the patients with critical illness demonstrate some fluctuations in hexose over time, and that the detection of this blood plasma metabolite is a dynamic process. Patients were neither hyper- nor hypo-glycemic according to their clinical glucose levels (also a 6-carbon sugar-data not shown), and this is closely monitored at the PICU bedside, given blood

171 glucose levels have been previously demonstrated to adversely affect patient outcomes, especially in  
 172 the case of hyperglycemia [25].

173 Remaining metabolites of interest include *p*-hydroxybenzoate with exception of the 72 hours'  
 174 time point, reveal that ECMO patients have lower relative concentrations than MODS patients, and  
 175 TCDCa, which is consistently lower in sedation-control patients, as compared to both MODS and  
 176 ECMO. TCDCa is a maker of liver injury, which is still elevated after 8 days for MODS and ECMO  
 177 patients. It is believed that shock liver common in this patient population usually subsides after a  
 178 few days, from our results we may speculate that this metabolite is still present at the 8<sup>th</sup> day post-  
 179 study enrollment. Lastly, keto-isovalerate like hexose and TCDCa has higher relative  
 180 concentrations for both MODS and ECMO patients compared to sedation-controls at both baseline  
 181 and 72 hours (at 8-days similar patterning, however VIP score <1.0). Additional metabolites of note  
 182 include lactate (VIP score ≥1.5) which would be expected in this group of patients [24], which is  
 183 highest in ECMO patients, second in MODS and lowest in the sedation-controls at the 72-hour time  
 184 point.  
 185  
 186

**Figure 3:** Important features identified by PLS-DA at baseline (A), 72 hours (B), and 8 days (C).



187

188 **Figure 3:** The colored boxes on the right indicate the relative concentrations of the corresponding  
 189 metabolite in each group under study. TCDCa: tauro-chenodeoxycholic acid.  
 190

### 191 3.3 Repeated Measures Over 3 Time Points

192 Furthermore, it was of interest to determine whether any of those metabolites identified by PLS-  
 193 DA with high VIP scores were statistically significant over time, as this may provide additional  
 194 understanding and potential biomarker identification of this cohort of untargeted metabolites.  
 195 When comparing to sedation-controls and correcting for Bonferonni adjustment for repeated  
 196 measures (P-value <0.008), both hexose and *p*-hydroxybenzoate were significant at, at least one time  
 197 point (Table 1).  
 198  
 199

200  
201  
202

**Table 1:** Repeated measures summary statistics for VIP  $\geq 2.0$  at baseline (A), 72 hours (B), and 8 days (C).


Metabolites	Hydroxyphenylacetic acid				2,3_dihydroxybenzoic acid				2-keto-isovalerate				Deoxyribose phosphate				Hexose				p-hydroxybenzoate				TCDCA			
	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value
Sedation (n=4)	47.40	53.93	44.87		16.00	10.56	13.58		6.52	0.97	6.63		6.79	4.60	6.71		15.80	3.26	14.37		53.12	7.66	53.00		0.22	0.323	0.08	
MODS BL (n=16)	1.82	5.29	0.43	P = 0.1900	1.81	2.63	0.74	P = 0.0760	11.83	8.64	10.03	P = 0.0291	1.09	1.12	0.73	P = 0.0907	37.22	24.03	30.55	P = 0.0031	65.01	36.71	56.51	P = 0.2476	2.53	4.14	0.77	P = 0.0422
ECMO BL (n=8)	4.72	10.12	0.81	P = 0.2146	10.98	14.87	4.80	P = 0.5631	9.33	3.91	9.41	P = 0.0879	2.25	3.25	1.15	P = 0.0733	21.03	19.43	23.88	P = 0.4799	26.59	20.68	15.73	P = 0.3170	14.30	25.76	2.53	P = 0.1660
MODS 72h (n=15)	6.94	12.2	2.39	P = 0.2331	2.10	3.15	1.23	P = 0.0804	10.60	5.07	8.18	P = 0.0127	0.79	0.65	0.62	P = 0.0802	9.79	12.38	0.19	P = 0.1228	19.16	15.29	13.74	P = 0.0251	11.87	24.91	1.93	P = 0.1037
ECMO 72h (n=7)	7.87	7.65	6.7	P = 0.2410	5.12	4.39	4.32	P = 0.0366	9.78	4.33	7.91	P = 0.0981	1.40	0.77	1.31	P = 0.1025	2.94	6.76	0.10	P = 0.0065	41.73	20.51	39.74	P = 0.0482	9.20	9.10	4.95	P = 0.0402
MODS 8d (n=8)	24.04	19.50	20.97	P = 0.4629	2.54	1.85	1.38	P = 0.0855	14.04	6.96	11.71	P = 0.0172	0.53	0.57	0.27	P = 0.0729	2.77	7.46	0.14	P = 0.0083	24.57	23.82	14.20	P = 0.0021	792.38	2208	8.05	P = 0.3441
ECMO 8d (n=6)	13.66	12.16	10.70	P = 0.3062	4.68	7.96	1.45	P = 0.0878	9.70	5.10	7.87	P = 0.1874	0.77	0.34	0.68	P = 0.0793	0.08	0.03	0.07	P = 0.0024	9.05	3.047	9.20	P < 0.0001	6.66	7.604	4.15	P = 0.0929

203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215

**Table 1.** Independent T-test performed (assuming equal variances); \*F-test for equal variances was  $P = < 0.05$  Welch-test (assuming unequal variances) was used; P-values less than 0.008 were deemed significant, after the Bonferonni adjustment; comparing MODS and ECMO samples to sedation-controls; TCDCA: tauro-chenodeoxycholic acid.

Box and whisker-plots were generated to be able to visualize the distribution of samples over time (Figure 4). From this we can visualize a large spread of patient blood plasma metabolite values, and that the values change over the three time points. More frequent and intensive sampling would be necessary to determine exact distribution for the acute, stabilization and recovery phases of MODS and ECMO patients, using a metabolic platform. This illustrates the complexity and the dynamic nature of sampling for this patient population.

**Figure 4:** Top two metabolites with significant differences from sedation-controls over 8-days.



216  
217  
218  
219  
220  
221  
222

**Figure 4:** Box and whisker plots, which include the median, the interquartile range (box), the outer range (whiskers) and pictorially summarize the central tendency, dispersion, skewness, and extremes of the dataset using a linear scale. MODS: multi-organ dysfunction syndrome; ECMO: extracorporeal membrane oxygenation; BL: baseline; 72: 72-hour time point; 8D: 8-day time point. Stars denote statistical significance from Independent T-test, or Welch-test as compared to sedation-controls.

### 223 3.4 Internal Validation

224 Kendall's tau-b test was used for internal validation, and revealed a positive correlation between  
225 creatinine and the respective creatinine metabolite at all three time points (baseline:  $\tau_b=0.708$ ,  $p=0.000$ ;  
226 72 hours:  $\tau_b=0.511$ ,  $p=0.001$ ; 8 days:  $0.684$ ,  $p=0.001$ ) (Supplemental Figure 3). While the three  
227 coefficients yielded similar results, the skewness and heteroskedasticity of the data violate the  
228 assumptions for Pearson's  $r$ . Spearman's Rho and Kendall's Tau are both non-parametric and

229 acceptable to use in this case. Spearman's Rho measures the rank correlation (how the ranks of the  
230 x and y values align), and Kendall's Tau measures the percent of concordant pairs, which is also  
231 based on ranks but considered to be a more robust measure. Creatinine was found to be high at  
232 baseline, which correlated with clinical creatinine values.

#### 233 4. Discussion

234 Untargeted analyses are intended to provide a means for finding differences in abundance  
235 across samples or groups of samples. Multivariate statistical techniques are therefore well suited to  
236 analysis of untargeted metabolomics data. MetaboAnalyst is a web-based platform created and  
237 developed by the Wishart group from the University of Alberta, offering R-based software for public  
238 use [20,26], and was the software of choice for this analysis.

239 From these preliminary results we may glean a few main findings: 1) metabolites of MODS  
240 and ECMO patients contain both Phase I and Phase II metabolites; 2) are dynamic in nature; 3)  
241 contain both potentially clinically relevant findings (such as TCDCA), as well as those of benign  
242 ( $\pm$ inert) function, as normally metabolized and excreted through downstream organ systems (renal,  
243 digestive); 4) metabolites can be measured and qualified in blood plasma of critically ill pediatric  
244 patients using an untargeted approach, which correlated to clinical values for routine care (e.g.  
245 creatinine).

246 Phase I and Phase II metabolites were detected amongst the 66 values analyzed. Recent  
247 evidence suggests that gut microbiome influences blood metabolites [27], which undergo Phase I  
248 metabolism through oxidation (R-OH), reduction (R-SH), or hydrolysis (R-NH<sub>2</sub>), and Phase II  
249 metabolism through sulfation (R-SO<sub>3</sub>H), glucuronidation (R-Gluc) and glutathione conjugation (R-  
250 Gl). This may suggest that there are greater metabolic influences beyond the scope of this study  
251 that need to be controlled for in future work, such as including gut microbiome profiles.

252 *p*-hydroxybenzoate, is thought to be produced via two major pathways: 1) microbial oxidation  
253 of petroleum derivative toluene into *p*-hydroxybenzoate, as described for *Pseudomonas* species [28];  
254 and 2) the *de novo* bioproduction of *p*-hydroxybenzoate from amino acids (tyrosine, tryptophan,  
255 phenylalanine) through an intermediate chorismate, via the enzyme chorismate lyase (UbiC) [29].  
256 *p*-hydroxybenzoate (paraben and alkyl ester derivative) is commercially used as a preservative and  
257 antimicrobial agent in pharmaceutical and cosmetic industry [30], and therefore may be from an  
258 exogenous source. The second possibility is an endogenous source, which has been described in  
259 *Escherichia coli* [31] and *Mycobacterium tuberculosis* [32], as produced from glucose, and can be toxic at  
260 higher-concentrations. Lower levels of *p*-hydroxybenzoate as observed in our MODS and ECMO  
261 patients at day 8 is a Phase I metabolite, and may be an indication of a gut bacteria dysbiosis (impaired  
262 microbiota), and to date has not been described in this patient population.

263 The most dynamic metabolite described herein is hexose which reflects the fluctuating energetic  
264 state of the patients. Low hexose at the third time point (8 days-post MODS diagnosis and into their  
265 PICU admission) could be a sign of energy deficiency, however we know that the patients were under  
266 close monitoring and by 72 hours were all receiving some nutritional intervention [12], after largely  
267 being *nil per os* at baseline. Blood glucose control has been further evaluated in Covid-19 patients,  
268 and is of ongoing concern given reports of higher mortality and multi-organ injury [33]. HPLA, a  
269 phenylcarboxylic acid, has been speculated to be a marker of sepsis in adult cardiac surgery, however  
270 requires further validation [34].

271 Cholesterol breaks down in the liver to produce primary bile acids, one being chenodeoxycholic  
272 acid, which together with taurocholic acid produces a conjugated bile acid TCDCA and excreted in  
273 the intestine, constituting our enterohepatic circulation. In spite of normalizing liver enzymes  
274 (alanine transaminase (ALT) Aspartate transaminase (AST)) in this patient population as previously  
275 reported [11], TCDCA remained elevated as compared to sedation-controls at the 8-day time point.  
276 This indicates that the metabolic profile may illustrate a different landscape on patient recovery, and  
277 metabolites may be organ specific.

278 Limitations of the work include a low sample volume, capturing high-abundance metabolites,  
279 and sample integrity may have been compromised by a previous freeze-thaw cycle. A second cohort

280 study would be necessary for further metabolite identification and validation to explore their clinical  
281 utility.

## 282 5. Conclusions

283 It is feasible to measure blood plasma metabolites in pediatric patients with MODS and  
284 undergoing ECMO treatment. Metabolites may be benign or significant in describing a patient's  
285 pathophysiology, fluctuate over time and require operator interpretation.

## 286 6. Abbreviations

287

288 HPLA: hydroxyphenylacetic acid; LC-MS: Liquid chromatography-mass spectrometry; MODS: multi-  
289 organ dysfunction syndrome; PICU: pediatric intensive care unit; PLS-DA: partial least squares-  
290 discriminant analysis; VA-ECMO: veno-atrial extracorporeal membrane oxygenation; VIP: variance  
291 of importance; TCDCA: tauro-chenodeoxycholic acid.

292 **Supplementary Materials:** Table S1: Metabolites identified n=115, metMz-mass over charge ratio, metRt-  
293 retention time, compound name, and compound ID listed; Figure S1: a) Metabolic actions of 115 metabolites  
294 identified; b) Ontological sources of 115 metabolites identified, taken from Human Metabolite Data Base  
295 (HMDB) (<https://hmdb.ca/metabolites/>); Figure S2: Clustering result shown as heatmaps at baseline (A), 72  
296 hours (B), and 8 days (C); Figure S3: Correlation of clinical creatinine to untargeted metabolite value(s).

297 **Author Contributions:** SR, DG and ML conceived of the original study design, screened, recruited, and collected  
298 all samples. Sample processing, peak findings, annotation, and quantification for metabolites was performed by  
299 TL. ML and AK performed all statistical and bioinformatic analysis. CK contributed to the annotation of  
300 individual metabolites. SR, DG, ML, AK, CK, BP, DS, JP and TL all contributed to the writing and editing of  
301 the manuscript.

302 **Funding:** Funding for this project was provided for SR, ML by Spectrum Health Office of Research (SHOR)  
303 funding initiative for precision medicine (#R51100431217), Helen DeVos Children's Hospital Foundation  
304 (HDVCH), grant (#R51100881018), and HDVCH Foundation grant (DG, SR, ML). NIH Office of the Director  
305 and NIEHS grant K01ES025435 (JWP).

306 **Acknowledgments:** The authors would like to thank the PICU staff at HDVCH for their support in the  
307 completion of this study and various contributions. Dr. David Tack and Dr. Alan Davis, for their additional  
308 statistical support.

309 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the  
310 study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to  
311 publish the results.

## 312 References

- 313 1. Leimanis Laurens, M.L.; Kraus-Friedberg, C.; Kar, W.; Sanfilippo, D.; Rajasekaran, S.; Comstock, S.S.  
314 Dietary Intake Influences Metabolites in Infants: A Scoping Review. *Nutrients* **2020**, *12*, 2073.
- 315 2. Shen, B.; Yi, X.; Sun, Y.; Bi, X.; Du, J.; Zhang, C.; Quan, S.; Zhang, F.; Sun, R.; Qian, L., et al. Proteomic  
316 and Metabolomic Characterization of COVID-19 Patient Sera. *Cell* **2020**, *182*, 59-72.e15,  
317 doi:10.1016/j.cell.2020.05.032.
- 318 3. Kyle, J.E.; Burnum-Johnson, K.E.; Wendler, J.P.; Einfeld, A.J.; Halfmann, P.J.; Watanabe, T.; Sahr, F.;  
319 Smith, R.D.; Kawaoka, Y.; Waters, K.M., et al. Plasma lipidome reveals critical illness and recovery from  
320 human Ebola virus disease. *Proc Natl Acad Sci U S A* **2019**, *116*, 3919-3928, doi:10.1073/pnas.1815356116.
- 321 4. Louis, P.; Hold, G.L.; Flint, H.J. The gut microbiota, bacterial metabolites and colorectal cancer. *Nature*  
322 *reviews. Microbiology* **2014**, *12*, 661-672, doi:10.1038/nrmicro3344.



- 323 5. Lai, F.Y.; Erratico, C.; Kinyua, J.; Mueller, J.F.; Covaci, A.; van Nuijs, A.L. Liquid chromatography-  
324 quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans:  
325 investigation on seven phenethylamine-based designer drugs. *Journal of pharmaceutical and biomedical*  
326 *analysis* **2015**, *114*, 355-375, doi:10.1016/j.jpba.2015.06.016.
- 327 6. Reed, G.A. Stability of Drugs, Drug Candidates, and Metabolites in Blood and Plasma. *Current protocols*  
328 *in pharmacology* **2016**, *75*, 7.6.1-7.6.12, doi:10.1002/cpph.16.
- 329 7. Shin, S.Y.; Fauman, E.B.; Petersen, A.K.; Krumsiek, J.; Santos, R.; Huang, J.; Arnold, M.; Erte, I.; Forgetta,  
330 V.; Yang, T.P., et al. An atlas of genetic influences on human blood metabolites. *Nature genetics* **2014**, *46*,  
331 543-550, doi:10.1038/ng.2982.
- 332 8. Beger, R.D.; Dunn, W.; Schmidt, M.A.; Gross, S.S.; Kirwan, J.A.; Cascante, M.; Brennan, L.; Wishart,  
333 D.S.; Oresic, M.; Hankemeier, T., et al. Metabolomics enables precision medicine: "A White Paper,  
334 Community Perspective". *Metabolomics* **2016**, *12*, 149, doi:10.1007/s11306-016-1094-6.
- 335 9. Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. *Nature*  
336 *reviews. Drug discovery* **2016**, *15*, 473-484, doi:10.1038/nrd.2016.32.
- 337 10. Prokop, J.W.; Shankar, R.; Gupta, R.; Leimanis, M.L.; Nedveck, D.; Uhl, K.; Chen, B.; Hartog, N.L.; Van  
338 Veen, J.; Sisco, J.S., et al. Virus-induced genetics revealed by multidimensional precision medicine  
339 transcriptional workflow applicable to COVID-19. *Physiological genomics* **2020**, *52*, 255-268,  
340 doi:10.1152/physiolgenomics.00045.2020.
- 341 11. Shankar, R.; Leimanis, M.L.; Newbury, P.A.; Liu, K.; Xing, J.; Nedveck, D.; Kort, E.J.; Prokop, J.W.; Zhou,  
342 G.; Bachmann, A.S., et al. Gene expression signatures identify paediatric patients with multiple organ  
343 dysfunction who require advanced life support in the intensive care unit. *EBioMedicine* **2020**, *62*, 103122,  
344 doi:<https://doi.org/10.1016/j.ebiom.2020.103122>.
- 345 12. Leimanis-Laurens, M.L.; Ferguson, K.; Wolfrum, E.; Boville, B.; Sanfilippo, D.; Lydic, T.; Prokop, J.;  
346 Rajasekaran, S. Pediatric Multi-Organ Dysfunction Syndrome: Analysis by an Untargeted Shotgun  
347 Lipidomic Approach Reveals Low-abundance Plasma Phospholipids and Dynamic Recovery Over 8-  
348 Day Period, a Single-Center Observational Study. *medRxiv* **2020**, 10.1101/2020.11.24.20237891,  
349 2020.2011.2024.20237891, doi:10.1101/2020.11.24.20237891.
- 350 13. Proulx, F.; Fayon, M.; Farrell, C.A.; Lacroix, J.; Gauthier, M. Epidemiology of sepsis and multiple organ  
351 dysfunction syndrome in children. *Chest* **1996**, *109*, 1033-1037, doi:10.1378/chest.109.4.1033.
- 352 14. Typpo, K.V.; Petersen, N.J.; Hallman, D.M.; Markovitz, B.P.; Mariscalco, M.M. Day 1 multiple organ  
353 dysfunction syndrome is associated with poor functional outcome and mortality in the pediatric  
354 intensive care unit. *Pediatr Crit Care Med* **2009**, *10*, 562-570, doi:10.1097/PCC.0b013e3181a64be1.
- 355 15. Typpo, K.; Watson, R.S.; Bennett, T.D.; Farris, R.W.D.; Spaeder, M.C.; Petersen, N.J.; Pediatric Existing  
356 Data Analysis, I.; Pediatric Acute Lung, I.; Sepsis Investigators, N. Outcomes of Day 1 Multiple Organ  
357 Dysfunction Syndrome in the PICU. *Pediatr Crit Care Med* **2019**, *20*, 914-922,  
358 doi:10.1097/PCC.0000000000002044.
- 359 16. Brain, M.J.; Butt, W.W.; MacLaren, G. Physiology of Extracorporeal Life Support (ECLS). In  
360 *Extracorporeal Life Support for Adults.*, G., S., Ed. Humana Press, New York, NY.: 2016; Vol. 16, pp. 1-60.
- 361 17. Busik, J.V.; Reid, G.E.; Lydic, T.A. Global analysis of retina lipids by complementary precursor ion and  
362 neutral loss mode tandem mass spectrometry. *Methods Mol Biol* **2009**, *579*, 33-70, doi:10.1007/978-1-  
363 60761-322-0\_3.
- 364 18. Luo, B.; Groenke, K.; Takors, R.; Wandrey, C.; Oldiges, M. Simultaneous determination of multiple  
365 intracellular metabolites in glycolysis, pentose phosphate pathway and tricarboxylic acid cycle by

- 366 liquid chromatography-mass spectrometry. *J Chromatogr A* **2007**, 1147, 153-164,  
367 doi:10.1016/j.chroma.2007.02.034.
- 368 19. Clasquin, M.F.; Melamud, E.; Rabinowitz, J.D. LC-MS data processing with MAVEN: a metabolomic  
369 analysis and visualization engine. *Curr Protoc Bioinformatics* **2012**, Chapter 14, Unit14 11,  
370 doi:10.1002/0471250953.bi1411s37.
- 371 20. Chong, J.; Wishart, D.S.; Xia, J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative  
372 Metabolomics Data Analysis. *Curr Protoc Bioinformatics* **2019**, 68, e86, doi:10.1002/cpbi.86.
- 373 21. Mevik, B.-H.; Wehrens, R. The pls Package: Principal Component and Partial Least Squares Regression  
374 in R. *Journal of Statistical Software* **2007**, 18, doi:<http://dx.doi.org/10.18637/jss.v018.i02>.
- 375 22. Kuhn, M. caret: Classification and Regression Training. Williams., C.f.J.W.a.S.W.a.A., Ed. 2008.
- 376 23. Bijlsma, S.; Bobeldijk, I.; Verheij, E.R.; Ramaker, R.; Kochhar, S.; Macdonald, I.A.; van Ommen, B.;  
377 Smilde, A.K. Large-Scale Human Metabolomics Studies: A Strategy for Data (Pre-) Processing and  
378 Validation. *Analytical Chemistry* **2006**, 78, 567-574, doi:10.1021/ac051495j.
- 379 24. Banacos, P.C. Box and whisker plots for local climate datasets interpretation and creation using Excel  
380 2007/2010. U.S. Department of Commerce, National Oceanic and Atmospheric Administration, National  
381 Weather Service] **2011**.
- 382 25. Patki, V.K.; Chougule, S.B. Hyperglycemia in critically ill children. *Indian J Crit Care Med* **2014**, 18, 8-13,  
383 doi:10.4103/0972-5229.125427.
- 384 26. Chong, J.; Soufan, O.; Li, C.; Caraus, I.; Li, S.; Bourque, G.; Wishart, D.S.; Xia, J. MetaboAnalyst 4.0:  
385 towards more transparent and integrative metabolomics analysis. *Nucleic Acids Research* **2018**, 46, W486-  
386 W494, doi:10.1093/nar/gky310.
- 387 27. Wikoff, W.R.; Anfora, A.T.; Liu, J.; Schultz, P.G.; Lesley, S.A.; Peters, E.C.; Siuzdak, G. Metabolomics  
388 analysis reveals large effects of gut microflora on mammalian blood metabolites. *Proc Natl Acad Sci U S*  
389 *A* **2009**, 106, 3698-3703, doi:10.1073/pnas.0812874106.
- 390 28. S. Miller Jr, E.; W. Peretti, S. Bioconversion of toluene to p-hydroxybenzoate . via the construction and  
391 characterization of a recombinant *Pseudomonas putida*. *Green Chemistry* **1999**, 1, 143-152,  
392 doi:10.1039/A901383K.
- 393 29. Verhoef, S.; Ruijsenaars, H.J.; de Bont, J.A.M.; Wery, J. Bioproduction of p-hydroxybenzoate from  
394 renewable feedstock by solvent-tolerant *Pseudomonas putida* S12. *Journal of Biotechnology* **2007**, 132, 49-  
395 56, doi:<https://doi.org/10.1016/j.jbiotec.2007.08.031>.
- 396 30. Lindsey, A.S.; Jeskey, H. The Kolbe-Schmitt Reaction. *Chemical Reviews* **1957**, 57, 583-620,  
397 doi:10.1021/cr50016a001.
- 398 31. Barker, J.L.; Frost, J.W. Microbial synthesis of p-hydroxybenzoic acid from glucose. *Biotechnology and*  
399 *Bioengineering* **2001**, 76, 376-390, doi:<https://doi.org/10.1002/bit.10160>.
- 400 32. Stadthagen, G.; Korduláková, J.; Griffin, R.; Constant, P.; Bottová, I.; Barilone, N.; Gicquel, B.; Daffé, M.;  
401 Jackson, M. p-Hydroxybenzoic Acid Synthesis in *Mycobacterium tuberculosis*. *Journal of Biological*  
402 *Chemistry* **2005**, 280, 40699-40706, doi:10.1074/jbc.M508332200.
- 403 33. Zhu, L.; She, Z.G.; Cheng, X.; Qin, J.J.; Zhang, X.J.; Cai, J.; Lei, F.; Wang, H.; Xie, J.; Wang, W., et al.  
404 Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type  
405 2 Diabetes. *Cell Metab* **2020**, 31, 1068-1077.e1063, doi:10.1016/j.cmet.2020.04.021.
- 406 34. Beloborodova, N.V.; Khodakova, A.S.; Olenin, A.J. Are phenylcarboxylic acids really markers in severe  
407 sepsis? *Critical Care* **2009**, 13, P41-P41, doi:10.1186/cc8097.
- 408